Davita Inc (NYSE:DVA) – KeyCorp issued their FY2018 earnings per share (EPS) estimates for shares of Davita in a report issued on Tuesday. KeyCorp analyst J. Gurda expects that the company will post earnings per share of $3.41 for the year. KeyCorp has a “Hold” rating on the stock. KeyCorp also issued estimates for Davita’s FY2019 earnings at $3.92 EPS.

Davita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.13). The business had revenue of $3.92 billion during the quarter, compared to the consensus estimate of $3.91 billion. Davita had a net margin of 3.40% and a return on equity of 13.31%. The firm’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the company posted $0.95 EPS.

A number of other analysts have also commented on the company. Royal Bank of Canada reissued a “hold” rating and set a $64.00 price target on shares of Davita in a research note on Wednesday, September 6th. J P Morgan Chase & Co downgraded Davita from a “neutral” rating to an “underweight” rating in a report on Monday, October 9th. Raymond James Financial upgraded Davita from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $65.00 to $84.00 in a report on Thursday, December 7th. Robert W. Baird restated a “hold” rating and set a $63.00 price objective on shares of Davita in a report on Friday, November 10th. Finally, SunTrust Banks set a $57.00 price objective on Davita and gave the company a “hold” rating in a report on Sunday, October 15th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $73.33.

Davita (NYSE:DVA) traded down $2.27 on Friday, hitting $69.03. The stock had a trading volume of 2,700,600 shares, compared to its average volume of 1,668,829. The firm has a market cap of $13,492.22, a price-to-earnings ratio of 20.37, a P/E/G ratio of 14.38 and a beta of 0.97. Davita has a 12 month low of $52.51 and a 12 month high of $71.47. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79.

Several institutional investors and hedge funds have recently modified their holdings of DVA. Schroder Investment Management Group raised its stake in shares of Davita by 769.0% in the third quarter. Schroder Investment Management Group now owns 434,191 shares of the company’s stock valued at $25,387,000 after buying an additional 384,224 shares during the period. Canada Pension Plan Investment Board increased its stake in Davita by 14.7% in the 3rd quarter. Canada Pension Plan Investment Board now owns 444,358 shares of the company’s stock worth $26,390,000 after acquiring an additional 56,988 shares during the last quarter. Speece Thorson Capital Group Inc. increased its stake in Davita by 14.5% in the 3rd quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock worth $19,075,000 after acquiring an additional 40,667 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its holdings in shares of Davita by 1,987.3% in the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock worth $2,448,000 after purchasing an additional 39,746 shares in the last quarter. Finally, Airain ltd purchased a new position in shares of Davita in the 2nd quarter worth about $2,234,000. Hedge funds and other institutional investors own 85.32% of the company’s stock.

In other Davita news, insider Charles Berg sold 7,048 shares of the business’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $69.24, for a total value of $488,003.52. Following the transaction, the insider now owns 5,359 shares of the company’s stock, valued at $371,057.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Javier Rodriguez sold 22,532 shares of the business’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $67.48, for a total value of $1,520,459.36. Following the completion of the transaction, the chief executive officer now directly owns 210,317 shares in the company, valued at approximately $14,192,191.16. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 117,937 shares of company stock worth $8,028,379. 2.10% of the stock is owned by insiders.

Davita announced that its board has authorized a stock repurchase program on Tuesday, October 10th that allows the company to repurchase $1.50 billion in shares. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.

COPYRIGHT VIOLATION NOTICE: This article was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/15/davita-inc-forecasted-to-post-fy2018-earnings-of-3-41-per-share-dva.html.

About Davita

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Earnings History and Estimates for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.